Anticoagulant Activity of β₂-Glycoprotein I Is Potentiated by a Distinct Subgroup of Anticardiolipin Antibodies

 

PDF Download Buy Article Permissions and Reprints

Summary

Plasmas of 16 patients positive for both IgG anticardiolipin (aCL) antibodies and lupus anticoagulant (LA) antibodies were subjected to adsorption with liposomes containing cardiolipin. In 5 of these plasmas both the anticardiolipin and the anticoagulant activities were co-sedimented with the liposomes in a dose-dependent manner, whereas in the remaining cases only the anticardiolipin activity could be removed by the liposomes, leaving the anticoagulant activity (LA) in the supernatant plasma. aCL antibodies purified from the first 5 plasmas were defined as aCL-type A, while the term aCL-type B was used for antibodies in the other 11 plasmas, from which 2 were selected for this study.

Prolongation of the dRVVT was produced by affinity-purified aCL-type A antibodies in plasma of human as well as animal (bovine, rat and goat) origin. aCL-type B antibodies were found to be devoid of anticoagulant activity, while the corresponding supernatants containing LA IgG produced prolongation of the dRVVT only in human plasma.

These anticoagulant activities of aCL-type A and of LA IgG's were subsequently evaluated in human plasma depleted of β₂-glycoprotein I (β₂-GPI), a protein which was previously shown to be essential in the binding of aCL antibodies to anionic phospholipids. Prolongation of the dRVVT by aCL-type A antibodies was abolished using β₂-GPI deficient plasma, but could be restored upon addition of β₂-GPI. In contrast, LA IgG caused prolongation of the dRVVT irrespective of the presence or absence of β₂-GPI.

Since β₂-GPI binds to negatively-charged phospholipids and impedes the conversion of prothrombin by the factor Xa/Va enzyme complex (Nimpf et al., Biochim Biophys Acta 1986; 884: 142–9), comparison was made of the effect of aCL-type A and aCL-type B antibodies on the rate of thrombin formation in the presence and absence of β₂-GPI. This was measured in a system containing highly purified coagulation factors Xa, Va and prothrombin and lipid vesicles composed of 20 mole% phosphatidylserine and 80 mole% phosphatidylcholine. No inhibition on the rate of thrombin formation was observed with both types of aCL antibodies when either β₂-GPI or the lipid vesicles were omitted. Addition of β₂-GPI to the prothrombinase assay in the presence of lipid vesicles causes a time-dependent inhibition which was not affected by the presence of aCL-type B or non-specific IgG. In contrast, the presence of aCL-type A antibodies dramatically increased the anticoagulant effect of β₂-GPI. These data indicate that the anticoagulant activity of aCL-type A antibodies in plasma is mediated by β₂-GPI.

• References

• 1 Loizou S, McCrea JD, Rudge AC, Reynols R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay: standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-744
  PubMedGoogle Scholar
• 2 Exner T, Triplett D. Lupus antioagulants: characteristics, methods of laboratory detection and some clinical associations. Phospholipid-Binding Antibodies Harris EN, Exner T, Hughes GRV, Asherson RA. CRC Press, Inc: 1991: 141-58
  Google Scholar
• 3 Pengo V, Hein MJ, Thiagarajan P, Shapiro SS. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987; 70: 69-76
  PubMedGoogle Scholar
• 4 Exner T, Sahman N, Trudinger B. Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid polystyrene column. Biochem Biophys Res Commun 1988; 155: 1001-1007
  CrossrefPubMedGoogle Scholar
• 5 McNeil HP, Chesterman C, Krilis SA. Anticardiolipin antibodies and lupus anticoagulant comprise antibody subgroups with different phospholipid binding characteristics. Br J Haematol 1989; 73: 506-513
  CrossrefPubMedGoogle Scholar
• 6 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemostas 1991; 66: 629-632
  PubMedGoogle Scholar
• 7 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β₂-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA: 1990; 87: 4120-4124
  CrossrefPubMedGoogle Scholar
• 8 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) are directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
  CrossrefPubMedGoogle Scholar
• 9 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-178
  PubMedGoogle Scholar
• 10 Harris EN, Gharavi AE, Tincani A, Chan JKH, Englert H, Mantelli P, Allegro F, Ballestrieri G, Hughes GRV. Affinity purified anticardiolipin and anti-DNA antibodies. J Clin Lab Immunol 1985; 17: 155-162
  PubMedGoogle Scholar
• 11 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1276
  CrossrefPubMedGoogle Scholar
• 12 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874
  PubMedGoogle Scholar
• 13 Oosting JD, Derksen RHWM, Entjes TI, Bouma BN, de Groot PG. β₂-Glycoprotein I is essential for Lupus Anticoagulant determination. Submitted
  PubMedGoogle Scholar
• 14 Polz E. Isolation of a specific lipid binding protein from human serum by affinity chromatography using heparin sepharose. In: Protides of Biological Fluids. Peeters H. (ed) Oxford: Pergamon Press: 1979. pp 817-820
  Google Scholar
• 15 Rosing J, Tans G, Govers-Riemslag JW, Zwaal RFA, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-283
  PubMedGoogle Scholar
• 16 Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GH, Zwaal RFA. Prothrombinase activity of human platelets is inhibited by β₂-glycoprotein I. Biochim Biophys Acta 1986; 884: 142-149
  CrossrefPubMedGoogle Scholar
• 17 Kroll J, Larsen JK, Loft H, Ezban M, Wallevik K, Faber M. DNA-binding proteins in Yoshida ascites tumor fluid. Biochim Biophys Acta 1976; 434: 490-501
  CrossrefPubMedGoogle Scholar
• 18 Schousboe I. Addition of deoxycholate in electroimmunoassay and crossed immunofocusing for quantification of β₂-glycoprotein I and its subfractions. J Biochim Biophys Meth 1982; 6: 105-114
  PubMedGoogle Scholar
• 19 McNeil HP, Krilis SA. Antiphospholipid antibodies. Aust N Z J Med 1991; 21: 463-475
  CrossrefPubMedGoogle Scholar